Havens Advisors Top New Positions: Covidien plc (COV), Idenix Pharmaceuticals Inc. (IDIX) and Others
In its recent 13F filing with the U.S. Securities and Exchange Commission, Nancy Havens-Hasty's Havens Advisors has disclosed its long equity positions for the second quarter of 2014.
Press release distribution, EDGAR filing, XBRL, regulatory filings
NeuroMetrix debuted on NASDAQ on July 22,... )--Comcast Corporation today reported results for the quarter ended June 30, 2014.
Covidien plc Sees Strong Trading Volume After Dividend Announcement
Covidien plc saw strong trading volume on Wednesday following a dividend announcement from the company, AR Network reports.
Customer Interaction Solutions
Announcement under Irish Takeover Rules Relevant Securities in Issue - July 14, 2014
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc confirms that, as of the close of business on July 11, 2014, the Company's issued share capital, excluding treasury shares, consisted of 451,716,767 ordinary shares, par value US$0.20 per share .
Deutsche Bank Reiterates On Medtronic And Covidien Amid Acquisition Proposal
In a note released Tuesday morning, Deutsche Bank analyst Kristen Stewart reiterated a Buy rating on both Medtronic and Covidien plc and raised her price targets from $74.00 to $85.00 and from $93.00 to $114.00, respectively.
Covidien plc Downgraded to "Neutral" at BTIG Research
COV has been the subject of a number of other recent research reports. Analysts at Raymond James downgraded shares of Covidien plc from a "strong-buy" rating to an "outperform" rating in a research note on Friday.
's Top Downgrades
Analysts at Raymond James downgraded Covidien plc from "strong buy" to "outperform."
Covidien plc to Report Third-Quarter Fiscal 2014 Results on July 25, 2014
The call can be accessed in the following ways: By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-546-5021.